Binnopharm Group, a Russian pharmaceutical company, has announced the submission of a registration application for its leading drug, Neobutin, in the People’s Republic of China. The application was filed at the end of November 2024, positioning Neobutin as one of the first Russian pharmaceuticals to undergo the registration process in China.
Neobutin already holds valid registration certificates in Azerbaijan, Armenia, Belarus, Georgia, Kyrgyzstan, Moldova, and Uzbekistan. The drug is designed to treat abdominal discomfort and stands out for its optimal price-quality ratio, as well as the availability of a pediatric formulation.
Binnopharm Group is committed to a strategy of expanding its product range in both neighboring and distant foreign markets by introducing successful products to new regions. The company actively promotes drugs that have already proven effective in Russia, allowing it to supply the market with affordable and in-demand medications.
The active ingredient in Neobutin is trimebutine, known for effectively relieving pain, spasms, and discomfort in the abdominal area. Three drugs with this trade name are registered in the Russian registry of medicines. Binnopharm Group possesses the registration certificate for the granulated form of the drug, which is manufactured by Alium JSC.
